Lilly CEO-Designate Taurel Will Guide Company To Post-Prozac Future
Executive Summary
Lilly is returning to a home-grown pharmaceutical specialist to oversee the company's transition from Prozac to its next generation of pharmaceuticals.
You may also be interested in...
Lilly Restructuring Positions Leichleiter As Heir Apparent To CEO Taurel
Lilly's promotion of John Leichleiter to president and chief operating officer positions him as the likely successor to CEO Sidney Taurel
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011